Peer-reviewed veterinary case report
Angiogenic markers in dog lymphoma don't predict chemo survival
By Wolfesberger, B et al.·Published in Research in veterinary science·2012·Department for Companion Animals and Horses·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Angiogenic markers in canine lymphoma tissues do not predict survival times in chemotherapy treated dogs.
- Species:
- dog
Plain-English summary
A group of dogs with lymphoma (a type of cancer) was treated with chemotherapy, but researchers found that certain markers in their tissues, like VEGF and its receptors, did not predict how long the dogs would survive. Most of the samples showed high levels of VEGF, but despite this, the average survival time for the dogs was about 266 days. This means that while chemotherapy can help, the presence of these specific markers in lymphoma tissues doesn't give a clear indication of how well a dog will do.
People also search for: dog lymphoma treatment · canine cancer survival rates · chemotherapy for dogs with lymphoma
Abstract
Angiogenesis, which is essential for malignancies to progress, depends on various signalling proteins including vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors 1 and 2 (VEGFR-1 and VEGFR-2). Microvessel density (MVD) is frequently used to evaluate angiogenesis. This study assessed the relationship between expression of VEGF, VEGFR-1 and VEGFR-2, MVD and the survival time in dogs with lymphoma. VEGF, VEGFR-1 and VEGFR-2 expression was evaluated immunohistochemically and microvessel profiles were counted in 34 lymphoma samples. Seventy-nine percent of the samples showed high VEGF expression and 62% were highly positive for VEGFR-1; VEGFR-2 immunoreactivity was mostly negative. Dogs treated with chemotherapy had a median survival time of 266days, but no significant relationships were found between overall survival time, MVD and expression of VEGF, VEGFR-1 or VEGFR-2. In this study, VEGF its receptors and the MVD were no prognostic factors in dogs with lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/21596405/